GET DAILY SIGNALSDexCom (DXCM) Pulls Back -9.4% Over the Past Month Despite Solid Fundamentals
Key Takeaways
- DexCom shares traded near $80 in late October, down roughly 9.4% over the trailing 30 days after slipping from about $89 in mid-September.
- The pullback has unfolded despite solid fundamentals: second-quarter 2026 revenue rose 13% year over year, and the company raised the low end of its full-year guidance.
- Several analysts turned more constructive in October, including Barclays (initiated Overweight with a $115 target) and price-target increases from Mizuho, BTIG, and RBC.
- DexCom is scheduled to report third-quarter 2026 results on October 29, making the upcoming print a key near-term catalyst.
- Competitive dynamics in the continuous glucose monitoring (CGM) market, led by Abbott and Medtronic, remain central to the investment debate.
Current Market Snapshot
DXCM shares have drifted lower over the past month, giving back some of the gains that followed a strong second-quarter earnings report. After trading near $89 in mid-September, the stock has declined roughly 9.4% to trade around $80, marking one of the weaker stretches for the shares in recent months.
The move has come against a backdrop of uneven sentiment across the medical devices sector, where concerns over healthcare policy, tougher year-over-year comparisons, and a volatile macro environment have weighed on valuations. Even so, the analyst community has largely remained constructive on DXCM, with several firms raising price targets or initiating coverage in October. That disconnect—solid fundamentals and improving sell-side sentiment versus a softening share price—frames the current setup ahead of the company's next earnings release. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
DexCom (DXCM) Business Overview and Competitive Position
DexCom, Inc. is a San Diego–based medical technology company that pioneered and now leads the market for continuous glucose monitoring (CGM) systems. Founded in 1999, the company designs, manufactures, and markets wearable sensors that deliver real-time glucose readings to smartphones and smartwatches, helping people with diabetes and their care teams manage the condition more effectively.
The company's product portfolio centers on its Dexcom G6, G7, and G7 15 Day CGM systems, alongside Stelo, the first over-the-counter CGM cleared by the U.S. Food and Drug Administration. DexCom is also advancing a next-generation G8 platform and expanding internationally, where it has posted faster growth than in its core U.S. market. Investors follow the stock for its recurring, sensor-driven revenue model, expanding margins, and its position as a leader in a category with a large, underpenetrated addressable population. From what I see, the recurring revenue angle continues to stand out as a key strength.
Recent Developments Driving DXCM
DexCom's most recent earnings report, released in late July for the second quarter of 2026, showed revenue of about $1.31 billion, up 13% year over year, with U.S. revenue up 11% and international revenue up 19%. The company raised the low end of its full-year revenue outlook to a range of $5.18 billion to $5.25 billion and lifted margin guidance, and the stock rose roughly 8% in the following session.
Since then, the focus has shifted to product expansion and the broader CGM competitive landscape. In June 2026, the FDA cleared the Stelo sensor for children, making it the first over-the-counter CGM available for pediatric prediabetic and diabetic patients. DexCom also presented data from its CONNECT trial at the 2026 American Diabetes Association Scientific Sessions, showing meaningful A1C reductions in people with type 2 diabetes not using insulin.
In October, sell-side activity picked up. Barclays initiated coverage with an Overweight rating and a $115 price target, while BTIG raised its target to $96 from $90, Mizuho to $100 from $95, and RBC to $105, each citing growth potential in the CGM market. Analysts have also flagged potential headwinds, including tougher revenue comparisons and procedure-volume pressures tied to Affordable Care Act and Medicaid policy shifts. I’m watching this closely as the October 29 report approaches.
2026 Outlook and What Investors Should Watch
Looking ahead, DexCom's guidance calls for revenue of $5.18 billion to $5.25 billion in 2026, or roughly 11% to 13% growth, supported by continued adoption of the G7 15 Day sensor, the expansion of Stelo, and further international penetration. Over the longer term, the company has outlined targets through 2030 that include annual organic growth exceeding 10% and meaningful gross and operating margin expansion.
Investors will be watching several factors closely: the pace of G7 15 Day adoption, progress on the G8 platform, the competitive response from Abbott's FreeStyle Libre franchise and Medtronic, and any shifts in reimbursement or healthcare policy. Macro conditions—including interest rates and broader market volatility—as well as the October 29 earnings release, will also shape sentiment in the near term. As always, the company's ability to sustain double-digit growth while defending its margins will be central to the stock's trajectory.
Exploring AI Tools for Market Analysis
One tool I’ve found useful in my own research is Tickeron’s AI Trading Bots. It allows me to review automated strategies across different risk profiles and timeframes, helping identify signals that align with broader fundamental views like those around DXCM. This kind of platform can complement traditional analysis when evaluating setups ahead of events such as earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXCM in downward trend: 10-day moving average moved below 50-day moving average on October 06, 2026
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 58 cases where DXCM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DXCM as a result. In 58 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on October 16, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 204 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.343) is normal, around the industry mean (2.979). P/E Ratio (33.233) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement